Relevance to clinical practice: In an era where HIV prevention methods are rapidly improving, strategies for sexually transmitted infection testing, treatment, counselling and prevention remain vital to improve health. All healthcare providers are uniquely positioned to promote sexual health through the dissemination of accurate information.
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| INTRODUCTION
The introduction of pre-exposure prophylaxis (PrEP) in 2012 for HIV in the form of Truvada â (emtricitabine + tenofovir dispoproxil fumarate) provided a new tool to help prevent HIV transmission. PrEP is a once-daily pill that is simple to use with low toxicity and good efficacy in reducing the risk of HIV acquisition (World Health Organization, 2012b) . Event-based dosing of PrEP-at least one pill 24 hr before and one pill 24 hr after sex-is an alternative dosing form in some countries (Molina et al., 2015) . Globally, it is estimated men who have sex with men (MSM) have a 19.3-fold greater odds of becoming infected with HIV compared to the general population (United Nations Population Fund, 2015) . In the light of this, MSM are a high-risk population appropriately targeted for PrEP initiation.
The introduction of PrEP as an HIV prevention method is not without controversy, and concern has been raised that it may lead MSM to think that they no longer need other preventive measures such as condoms (United Nations Population Fund, 2015; Venter, Allais, & Richter, 2014) . The support for this concern is evidenced in qualitative PrEP studies which report 35%-60% of high-risk MSM believed that they would be less likely to use a condom if they were on PrEP (Brooks et al., 2012; Golub, Kowalczyk, Weinberger, & Parsons, 2010; Hoff et al., 2015) .
While PrEP reduces the risk of HIV transmission, it does not provide any protection against other sexually transmitted infections (STIs), which can only be prevented by consistent condom use, mutual monogamy or abstinence (World Health Organization, 2012b) . STIs disproportionally affect MSM and continue to escalate in this population (World Health Organization, 2012a) . The introduction of PrEP is viewed by many as fuelling the recent upsurge in STIs (Kennedy, 2014; World Health Organization, 2012b) . STIs continue to be a major public health issue, and it is estimated globally there are 357 million new cases a year (World Health Organization, 2012a) . Reports of STI treatment failure rates are between 13%-21% in MSM, and different
STIs have re-emerged with a vengeance such as resistant strains of gonorrhoea and chlamydia, ophthalmic and otic syphilis, and even neurosyphilis (Bissessor et al., 2015; World Health Organization, 2012a) .
In many cultures, MSM are unable to access sexual health services as homosexuality is illegal and in some cases punishable by death, leaving them at high risk for HIV acquisition (World Health Organization, 2007) . Even when healthcare access is not an issue, medical providers report being ill-equipped to discuss sexual health and are concerned that sexual risk behaviours, and in turn STI rates, will increase if they prescribe PrEP. Furthermore, PrEP for HIV prevention remains contentious because some medical providers fear they will be seen as condoning condomless sex (Venter et al., 2014) .
To help medical providers prescribe PrEP, the World Health Organization (2012b) has published clear guidelines that recommend the use of PrEP in conjunction with condoms.
The increase in the apparent incidence of STIs among PrEP users may be related to STI testing required by PrEP protocols in clinical practice (Cohen, Lo, Caceres, & Klausner, 2013) . Historically, similar patterns occurred with the introduction of highly active antiretroviral therapy (HAART) for HIV in the mid-1990s. As STI rates began to rise among MSM presenting for HIV treatment, some researchers hypothesised that risk compensation, rather than increased testing during the HIV treatment process, was to blame (Myers & Sepkowitz, 2013 • Condom use and sexual risk counselling at every encounter appear to be effective in decreasing risk behaviour.
STI testing should include extra-genital testing in MSM regardless of PrEP use, in order to prevent health deficits and onward transmission.
• Providing privacy for MSM to complete sexual health questionnaires improves accurate risk reporting in turn decreasing morbidity and mortality. suggests that PrEP alone cannot account for the observed increase in STI rates among its users. It may instead be that programmes targeting MSM for HIV/STI testing and treatment are actually the cause of the reported increase in STIs. Similarly, another biomedical intervention that had biases comparable to PrEP was the oral contraceptive pill, which many assumed would lead to adverse results and an increase in sexual risk behaviour (Fenton, 2010) . When the pill was first brought to market, it required a woman to be married.
Later, when the pill could be prescribed for any woman regardless of marital status, gonorrhoea diagnoses increased and the working theory was that the unintended consequences were due to condomless sex, rather than more effective testing protocols for STIs (Myers & Sepkowitz, 2013) that were implemented at the same time. A parallel debate continues among healthcare providers, political entities and the MSM community whether PrEP is a direct link to decrease in condom use among MSM secondary to a decreased fear of being infected with HIV-just as it was feared the pill would lead to a decrease in condom use secondary to a decreased fear of becoming pregnant.
| AIMS
The purpose of this study was to review the literature on the association of PrEP use with condom use, STI incidence and change in sexual behaviours, such as anal sex and number of partners in MSM.
The research questions were as follows:
How does PrEP use affect condom use in MSM?
2. How does PrEP use affect STI incidence in MSM?
3. How can transmission risks for HIV/STI (e.g., type of anal sex, number of partners) be assessed in MSM using PrEP?
3 | ME TH ODS
| Design
An adapted Cochrane Collaboration domain-based assessment tool was used to critically appraise the methodological components of each quantitative study (Higgins et al., 2011) , and the Mixed Methods Appraisal Tool (MMAT) (Pluye et al., 2011) was used to critically appraise qualitative and mixed-methods studies. Qualitative and mixed-methods studies were included as they are better suited for exploring the complexities of sexual risk perception, behaviour change and attitudes towards new biomedical prevention tools (Whittemore & Knafl, 2005) . (Bolan et al., 2015) ; and (iii) articles published prior to 2010 due to a paucity of data.
| Search methods

| Search results
The electronic database search generated 142 potential citations, published between January 2010-2016, and another three were identified by searching for sentinel studies (IPERGAY, PROUD, iPrEx). All titles and abstracts were screened and reviewed by the first author and Dr. David Vlahov, who has authored a body of work on HIV, risk behaviour and MSM. Initially, there was a disagreement regarding the inclusion of qualitative and mixed method studies as they did not include STI screening data, but upon further review, it was agreed the insights they provided into PrEP-related change in condom use, STIs and capturing change in sexual practices were valuable. Figure 1 presents a flow diagram of the selection and review process. After inclusion and exclusion criteria were met, and systematic reviews, practice guidelines, editorials, meeting abstracts, meta-analyses, duplicates and unrelated articles were excluded, the final number was 10. Table 1 displays the 10 reviewed studies, which were published between 2010-2016; three were randomised control trials (RCTs) (Grant et al., 2010; Marcus et al., 2013; Molina et al., 2015) : one began as an RCT but was changed to an open-label trial (McCormack et al., 2015) ; one was a community open-label trial (Liu et al., 2016) ; one was a prospective cohort study (Volk et al., 2015) ; one was a survey (Golub et al., 2010) , two were mixed methods (Brooks et al., 2012; Hoff et al., 2015) ; and one was qualitative (Hojilla et al., 2015) . The RCTs and open-label trials had Truvada provided by
| RESULTS
| Characteristics of the studies
Gilead at no cost to the participants (Grant et al., 2010; Liu et al., 2016; McCormack et al., 2015; Molina et al., 2015) The prospective cohort study was limited to individuals who accessed care through the Kaiser healthcare system. For that study, Truvada was not provided by Gilead and clients had a copayment towards drug cost between 30-50 USD (Volk et al., 2015) . Daily dosing of PrEP was used in nine studies, and event-based dosing was used in one study (Molina et al., 2015) .
| Inclusion and exclusion criteria for the studies
The methods and inclusion criteria varied considerably across these studies. The common elements extracted to facilitate comparisons included MSM age 18 or over who were HIV seronegative, condom use, sexual risk behaviour and STI data. Definitions of sexual risk included condomless anal intercourse, (receptive or insertive) and at least one partner in the past 3, 6 or 12 months (Brooks et al., 2012; Golub et al., 2010; Grant et al., 2010; Hoff et al., 2015; Hojilla et al., 2015; Liu et al., 2016; Marcus et al., 2013) .
Terms used to describe the target population varied among the studies: four studies referred to MSM as men having sex with men and transgender persons (Grant et al., 2010; Hojilla et al., 2015; Marcus et al., 2013; Molina et al., 2015) ; four studies only used the term MSM and did not refer to any other subgroups of people (Golub et al., 2010; Hoff et al., 2015; Volk et al., 2015) ; one study used the term "gay and bisexual" (Brooks et al., 2012) ; and three studies defined men who have sex with men as "male at birth" (Grant et al., 2010; Marcus et al., 2013; Volk et al., 2015) . Definitions of sexual risk varied as follows:
• Grant et al. (2010) : unprotected anal receptive sex in past 12 weeks; any transactional sex in past 6 months; known HIVpositive partner; any unprotected anal intercourse with partner of positive or unknown HIV status.
• Golub et al. (2010) : instances of substance use with at least one incident of unprotected anal intercourse (insertive or receptive) with a casual or serodiscordant male partner in last 3 months.
• Hojilla et al. (2015) : any condomless anal sex (insertive or receptive) with two or more male or transgender female partners in past 12 months.
• Brooks et al. (2012) : HIV-negative MSM in a serodiscordant relationship for 12 months or longer.
• Marcus et al. (2013) : any condomless anal sex (insertive or receptive).
• Hoff et al. (2015) : serodiscordant couples engaging in any anal sex (insertive or receptive) in past 3 months.
• Volk et al. (2015) : risk assessed by primary care provider before referral to PrEP clinic.
• Molina et al. (2015) : unprotected anal sex (insertive or receptive)
with at least two partners in past 6 months.
• McCormack et al. (2015) : previously attended one the 13 screen- ↔, no change.
• Liu et al. (2016) : condomless receptive anal sex with at least two male or transwomen partners; or at least two episodes of condomless anal sex (insertive or receptive) with at least one HIVinfected partner; or sex with a male or transgender partner and being diagnosed with syphilis or anal GC/CT.
Exclusion criteria included medical contraindications to PrEP (Grant et al., 2010; Hojilla et al., 2015; Liu et al., 2016; Marcus et al., 2013; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) , not meeting risk criteria (Brooks et al., 2012; Golub et al., 2010; Hoff et al., 2015) , and not agreeing to or not completing follow-up visits (Hojilla et al., 2015; Volk et al., 2015) . Participant retention rates in studies where drug or placebo was provided were 72%-78%, but over the course of all of the studies, response rates for behavioural measures decreased.
| Race
Participants were recruited from multiple locations including Peru, Ecuador, Brazil, Thailand, South Africa, USA, Canada, France and the UK. Race was not clearly defined in all of the studies, with some not mentioning race or ethnicity and instead merely stating the site of the trial (Grant et al., 2010; Marcus et al., 2013; Molina et al., 2015) .
Therefore, a comparison of differences in STI rates and condom use between races/ethnicities was not an element of review in this study.
| Location
All of the studies were located in urban areas with high HIV prevalence rates among MSM (25%-46%), such as San Francisco, New York, Miami, London, Paris, Montreal, Rio de Janerio, Chang Mai and Cape Town (Brooks et al., 2012; Centers for Disease Control and Prevention, 2013; Golub et al., 2010; Grant et al., 2010; Hoff et al., 2015; Hojilla et al., 2015; Liu et al., 2016; Marcus et al., 2013; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) .
| Socio-economic status
Quantifying education status and income of participants across the studies was problematic due to studies having been conducted in 10 countries with differing educational structures and levels and differing definitions of income levels (Brooks et al., 2012; Centers for Disease Control and Prevention, 2013; Golub et al., 2010; Grant et al., 2010; Hoff et al., 2015; Hojilla et al., 2015; Liu et al., 2016; Marcus et al., 2013; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) .
| Age
The age range in the quantitative studies was 18-68, three studies reported mean ages which ranged from 25-37 years old (Grant et al., 2010; Marcus et al., 2013; Volk et al., 2015) , one study only provided a range of 18-45+ (Liu et al., 2016) , and two studies reported a median age of 35 (McCormack et al., 2015; Molina et al., 2015) . The quantitative survey study had a smaller age range of 18-49 with a mean of 29 (Golub et al., 2010) . In the mixed-methods studies, the age range was 19-71 with a median age of 36 (Brooks et al., 2012; Hoff et al., 2015) . The qualitative study that used a framework analysis had a range of 21-63 with a median age of 37 (Hojilla et al., 2015) .
| Substance use
Substance use, including intravenous drug use, was not measured consistently across studies, and thus, it was not possible to draw conclusions about the associations between sexual risk behaviour and substance use. For example, two of the RCT studies included methamphetamine, ecstasy and gamma-hydroxybutyrate (McCormack et al., 2015; Molina et al., 2015) , and another only measured alcohol use (Grant et al., 2010) . The open-label study included amyl nitrite (poppers), erectile dysfunction drugs and heroin (Liu et al., 2016) , and the prospective cohort study included cocaine and methamphetamine. The predominant finding was that substance use did not influence adherence to PrEP but how substance use influenced condom use and sexual risk behaviours varied (Grant et al., 2010; Hojilla et al., 2015; Liu et al., 2016; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) .
| Measurements of risk behaviour
All of the studies collected individual risk behaviour data using multiple methods, including interviewer-administered questionnaires and surveys (Brooks et al., 2012; Grant et al., 2010; Liu et al., 2016; Marcus, 2013; McCormack et al., 2015) , secure email surveys (Volk et al., 2015) , computer-assisted structured interviews (Golub et al., 2010; Grant et al., 2010; Hoff et al., 2015) and data from daily diaries (McCormack et al., 2015) . Questions common across all studies included number of condomless anal receptive and insertive sex episodes, number of partners (both receptive and insertive anal with or without a condom) and intended or actual use of condoms since the last visit.
In one RCT study (Grant et al., 2010) , in which baseline risk behaviour was captured by computer-assisted self-interview (CASI) but follow-up risk behaviour was captured by in-person interview, study participants predominately reported no behaviour change or a decrease in risk behaviour. Similarly, the studies of Liu et al. (2016) and Marcus et al. (2013) , which used in-person interviews only, increase in reported risk behaviour between baseline and follow-up (Brooks et al., 2012; Golub et al., 2010; Hoff et al., 2015) . One cohort study (Volk et al., 2015) found that participants responding to emails from healthcare providers reported no change in sexual risk, while participants responding to emails from non-healthcare providers reported increased sexual risk between baseline and follow-up. Reliability for reporting risk during sexual activities has been shown to decrease over time (Kauth, St Lawrence, & Kelly, 1991) .
To control for decreased risk reporting, daily diaries and monthly questionnaires were initiated in one RCT, but were subsequently abandoned due to a low response rate. In contrast, baseline and 12-month questionnaires, by paper and pencil or computer, in the same study yielded a higher response rate (McCormack et al., 2015) .
| Condom use change
Condom use change associated with PrEP was variable throughout the studies reviewed. The data from the blinded RCTs showed either no change (Molina et al., 2015) or increased use of condoms and only a~4% decrease in condomless anal sex after stopping the study (Grant et al., 2010; Marcus et al., 2013) . Conversely, the open-label and cohort trials reported an increase in the number of condomless receptive anal sex partners if on PrEP (Liu et al., 2016; Volk et al., 2015) . In the PROUD study (McCormack et al., 2015) , participants were randomised to begin PrEP either at the start of the study or after 1 year. Those who began on PrEP reported a larger increase in receptive anal sex without a condom with ten or more partners (21% vs. 12%; p = .03, test for trend) at month 12 of the study. Participants also reported an increase of 14% in first time condomless receptive anal sex; however, there was no significant difference between placebo and PrEP groups, and therefore, the authors did not consider this to represent a behaviour change. This finding was also reflected in the secondary analysis of the iPrEx study: if a participant responded strongly believing, he was taking PrEP the mean number of partners increased from 7.7-12.8 (p = .04) (Marcus et al., 2013) . Conversely, the open-label and cohort trials reported an increase in the number of condomless receptive anal sex partners if on PrEP (Liu et al., 2016; Volk et al., 2015) .
In the Golub et al. (2010) Decreased condom use had interesting associations with a number of other variables. For example, in the iPrEx study participants under 25 years of age were more likely to report condomless anal receptive sex at follow-up than those age 25 or older (Grant et al., 2010; Marcus et al., 2013) . Conversely, in the mixed-methods studies older MSM were more likely to decrease condom use (Brooks et al., 2012; Hoff et al., 2015) . Situational factors, such as geographical location and place of sexual encounter, also affected condom use change, with San Francisco participants reporting the greatest decrease in condom use compared to other locations (Liu et al., 2016) , and encounters in bath houses more likely to involve condomless sex (Hojilla et al., 2015) . Decreased condom use was associated with certain relationship factors, for example, if an HIVnegative partner were using PrEP, his HIV-positive partner would feel more comfortable barebacking (Hoff et al., 2015) . Other variables that showed associations with decreased condom use included mental health issues, such as depression (Liu et al., 2016; Marcus et al., 2013) ; perception of partners being low risk (Hojilla et al., 2015) ; and socio-economic factors, such as higher income and having a college degree (Golub et al., 2010; Hoff et al., 2015) . Of note, substance use was found to decrease condom use (Golub et al., 2010; Hojilla et al., 2015) or have no effect on condom use change (Liu et al., 2016; McCormack et al., 2015; Volk et al., 2015) .
| Sexually transmitted infections
To verify whether condomless sex had occurred, participants in certain studies were tested for biomarkers of GC/CT (Liu et al., 2016; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) and syphilis (Grant et al., 2010; Liu et al., 2016; Marcus et al., 2013; McCormack et al., 2015; Molina et al., 2015) . The biomarkers used were all validated and are currently used in practice. Treatment for STIs was provided per local guidelines in all studies. There was no significant difference in STI rates between participants on PrEP and those not on PrEP in the RCT studies (Grant et al., 2010; Marcus et al., 2013; McCormack et al., 2015) .
Assessment and testing for STIs was completed at baseline in six studies, but how the information was collected was not uniform across the studies as shown in Table 2 . Three-point testing for GC/ CT (urethral, anal and pharyngeal) and syphilis was completed in four studies at baseline and every 12 weeks (Liu et al., 2016; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) . STI incidence was high in the studies that consistently screened for anal, pharyngeal, and urethral GC/CT, and syphilis. For example, two of the RCT studies found rectal GC/CT in 32%-39% of participants (McCormack et al., 2015; Molina et al., 2015) and syphilis infections ranged from 5%-11% (Liu et al., 2016; McCormack et al., 2015; Volk et al., 2015) .
The iPrEx study only analysed urethral GC/CT samples if leucocytes were present in the urine and urethral screening for asymptomatic urethritis occurred every 24 weeks. There were no anal biomarker tests for GC/CT and reporting relied on examination and self-reports of symptoms or exposure making syphilis the only STI with consistent biomarker testing (Grant et al., 2010) . STI rates were similar in treatment and placebo groups at all time points; there were no significant between-group differences in the numbers of subjects with gonorrhoea or chlamydia during follow-up. Syphilis cases decreased during follow-up in both treatment arms (p trend <.001) (Grant et al., 2010) . The PROUD study also found no significant difference in STI rates between participants on PrEP and those not on PrEP despite participants on PrEP reporting increased number of partners and an increase in receptive anal sex (McCormack et al., 2015) . Liu et al. (2016) found that 51% of participants were diagnosed with one STI (CT,GC or syphilis) at baseline, with an initial decrease in rectal and pharyngeal GC/CT at 6 months followed by an increase at 12 months (p < .05) and a final overall STI-positive rate similar to the baseline STI rate (Liu et al., 2016) . Two studies did not include baseline STI data (Molina et al., 2015; Volk et al., 2015) but found increases in STIs over time at multiple follow-up visits, specifically in anal GC/CT, despite no reported changes in number of partners and similar rates of condom use throughout.
The mixed-methods studies did not collect STI data; however, between 30%-40% of participants discussed being concerned about STI risk if they decreased condom use secondary to being on PrEP (Brooks et al., 2012; Hoff et al., 2015) . Neither the survey study (Golub et al., 2010) nor the framework analysis included questions or data regarding STIs (Hojilla et al., 2015) .
| Impact of risk reduction counselling on behaviour
All of the RCTs and open-label trials provided risk reduction counselling at least on a monthly basis, as well as condoms and lubricant (Grant et al., 2010; Liu et al., 2016; McCormack et al., 2015; Molina et al., 2015) . Only one study described implementing and training counsellors in the use of, a risk reduction model (RESPECT), and risk behaviours during that study did not change from baseline (Molina et al., 2015) . In contrast, in the Grant et al. (2010) blinded RCT where risk reduction counselling and HIV/STI tests were provided at the same visit, risk reporting decreased. In the prospective cohort study that implemented unspecified risk reduction counselling, reports of sexual risk increased from baseline (Volk et al., 2015) .
Conversely, in the open-label study number of anal sex partners decreased in a response to risk reduction counselling (Liu et al., 2016) .
In the two mixed-methods studies and the quantitative survey, participants did not receive any risk reduction counselling, condoms or lubricant because hypothetical scenarios were used (Brooks et al., 2012; Golub et al., 2010; Hoff et al., 2015) . This may account for the reports of increased risk behaviours compared to the studies were risk reduction counselling was included.
In the qualitative study, participants received risk reduction counselling, condoms and lubricant at every visit. The analysis of counselling notes revealed that the risk reduction counselling provided to PrEP users included guidance on serosorting (having sex with HIV-negative partners only), seroadaptation (asking sex partners their HIV status), and seropositioning (oral or insertive anal sex with HIV-positive partners) and condom use. Counselling on the combination of these methods is reported to decrease sexual risk behaviours in this cohort (Hojilla et al., 2015) .
| DISCUSSION
Our review found that offering PrEP services provides an opportunity for MSM to access sexual health care, testing, treatment and counselling that would not be accessed otherwise. Although STI rates were high in this population, we did not find any conclusive evidence that PrEP use leads to increased sexual risk behaviours.
Counselling regarding condom use and STI testing at every encounter improved compliance and should be a fundamental component trials used self-report of condom use, and the response rate was low. Regardless of response rate, validity of self-report is difficult to measure and is often influenced by the individual feeling compelled to report the "correct" answer (Zenilman et al., 1995) . This may explain why there was a 56%-74% report of no change in condom use in the studies where participants were counselled to use condoms (Grant et al., 2010; Hojilla et al., 2015; Liu et al., 2016; Marcus et al., 2013; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) . Furthermore, none of the studies included questions about condom use before PrEP initiation, making it impossible to assess whether "no change" meant using or not using condoms. And paradoxically, two of the trials reported an increase in condom use without any significant changes in STI rates, further suggesting that selfreport of condom use is methodologically unreliable.
Sexually transmitted infections biomarker analysis is a commonly used method for quantifying sexual risk behaviours such as condom use (Hewett et al., 2008; Hotton, Gratzer, & Mehta, 2012) . However, there are some behaviours for which biomarkers are ill-suited (e.g., sexual frequency or needle sharing) (Hojilla et al., 2015; Kauth et al., 1991; Weinhardt, Forsyth, Carey, Jaworski, & Durant, 1998) . The perception among healthcare professionals that PrEP will lead to increased risk behaviours (Venter et al., 2014; Wilton, Senn, Sharma, & Tan, 2015 ) has yet to be confirmed. A number of the studies reviewed here did show high overall rates of STIs in MSM on PrEP or placebo (33%-57%), yet none of them reported a significant change in STI rates between baseline and follow-up. In fact, one study found no change over time in rates of rectal GC/CT despite participants reporting increased number of partners and increased receptive anal sex (McCormack et al., 2015) . Furthermore, while there may be a perception that it is PrEP that leads to an increase in STI rates, many of the participants had never been tested There is some evidence within the reviewed studies that risk compensation may occur on PrEP. There was a common theme that PrEP reduced the anxiety around sexual acquisition of HIV (Brooks et al., 2012; Golub et al., 2010; Hoff et al., 2015; Hojilla et al., 2015) , thus creating a perception among MSM that the need for condom use is eliminated. For example, many HIV-seropositive partners expressed they would be comfortable engaging in condomless anal sex if their partner was on PrEP (Brooks et al., 2012; Golub et al., 2010; Hoff et al., 2015) . However, the influence of partners'
preference not to use condoms was not measured in many of the studies, even though this has been found to have a significant influence on condom use (O'Neal & Berteau, 2015) . Furthermore, a common finding was a change in sexual practice from being exclusively anally insertive, to experimenting with being anally receptive after PrEP initiation (Grant et al., 2010; Hojilla et al., 2015; McCormack et al., 2015; Molina et al., 2015; Volk et al., 2015) . This willingness to experiment sexually may be attributed to a reduction in anxiety of HIV acquisition.
In order to capture risk behaviour, the studies made an effort to collect individual risk behaviour using multiple methods that included interviewer-administered questionnaires (Liu et al., 2016; Marcus et al., 2013; McCormack et al., 2015) , secure email survey (McCormack et al., 2015; Volk et al., 2015) , CASI (Golub et al., 2010; Grant et al., 2010; Hoff et al., 2015; McCormack et al., 2015) , daily diaries and paper and pencil questionnaires (McCormack et al., 2015) , and review of counselling notes (Hojilla et al., 2015) . In the studies reviewed herein, CASIs produced better response rates than other methods used to capture sexual risk behaviour. This is consistent with the literature that has shown higher rates of risk behaviour reported in CASIs than in interviewer-administered questionnaires (Macalino, Celentano, Latkin, Strathdee, & Vlahov, 2002; (Kurth et al., 2004) . Participants questioned using CASI methodologies typically report number of partners and frequency of condomless sex more openly than those interviewed face-to-face, an observation that has been attributed to greater privacy for reporting socially sensitive behaviours (McAuliffe, DiFranceisco, & Reed, 2007) and socially acquiescent responses that occur with in-person interviews (Fenton, Johnson, McManus, & Erens, 2001 ). Behaviour disclosure is often influenced by the desire to create a positive social image (Holtgraves, 2004) , which may have been reflected in the results of in-person interviews. Such social desirability influence may explain why there was a decline in risk behaviour reports in one RCT where the baseline behaviour risk was captured by CASI but follow-up risk behaviours were captured by in-person interviews (Grant et al., 2010) .
The response rate for the secure email questionnaires was lower than for interviewer-administered questionnaires, which may have been a consequence of the higher level of language and computer literacy required for email compared to interviewer-administered questionnaires (Weinhardt et al., 1998) . Where participants were required to respond to an email received from a healthcare provider, the majority reported no change in sexual risk behaviour (Volk et al., 2015) , which may have been because this was perceived as being part of the medical record. None of the studies in this review included validity or reliability reports for the methods used to capture risk behaviour. Such reports are unfortunately uncommon in sexual health research, even though suitable methodologies have been developed and tested (McAuliffe et al., 2007) .
Additionally, in the studies reviewed, representation of MSM under age 25, who are considered to be at greatest risk for HIV/STIs, was low, 5%-30% (World Health Organization, 2012b). Data from the RCTs reflected this finding (Grant et al., 2010; Marcus et al., 2013; McCormack et al., 2015; Molina et al., 2015) with the majority of participants being in their thirties. One might speculate that this was due to decreased risk awareness or a lack of information regarding new HIV prevention tools (Underhill et al., 2015) . Barriers to younger PrEP users may include inexperience negotiating healthcare systems, reluctance to discuss sexual preferences with healthcare providers, fear of parents being informed and cost (Kubicek, Arauz-Cuadra, & Kipke, 2015) . For example, in the prospective cohort study (Volk et al., 2015) , which was set in a large US healthcare institution, the mean age of participants was 37. One possible explanation for this is that, while other studies provided PrEP free of charge, the Volk et al. (2015) study required a payment, which some younger MSM may not have been able to afford. Cost has been found to be a barrier to accessing PrEP and a barrier to adherence to other medications (Chakrapani et al., 2015; Eaddy, Cook, O'Day, Burch, & Cantrell, 2012; Gersh et al., 2014) . However, there are currently no data available outside of a study context regarding the effect of cost on adherence to PrEP. Volk et al. (2015) was also the only study requiring a primary healthcare provider determination of a need for PrEP. In contrast, screening in the other studies outside of a large healthcare system at "gay-friendly" sites merely required participants to state that they wanted PrEP.
However, even at such gay-friendly sites, participation by those under 25 did not increase (Grant et al., 2010; Liu et al., 2016; McCormack et al., 2015; Molina et al., 2015) . All of the studies included a HIV risk component in their inclusion criteria, which may have inadvertently alienated younger MSM. The low uptake of PrEP by young MSM has been identified in other studies and may be secondary to individuals not having established a gay identity, a misconception that PrEP is synonymous with promiscuity and a lack of insight into risk behaviour within communities with high HIV prevalence (Knight, Small, Carson, & Shoveller, 2016; Kubicek et al., 2015) . Healthcare professionals should take these factors into consideration when interpreting the available PrEP data for younger MSM. In view of the fact that younger MSM are one of the populations in which HIV rates are increasing, this review suggests that neither an individual's ability to pay nor a clinician's assessment of risk should be prerequisites for access to PrEP.
There are methodological concerns throughout all of the studies.
For instance, the mixed-methods and quantitative survey studies used hypothetical scenarios with a guaranteed 80% or greater protection against HIV without addressing participants' understanding of risk factors for HIV or STIs, making it difficult to extrapolate their findings to real world scenarios (Brooks et al., 2012; Golub et al., 2010; Hoff et al., 2015) . In addition, the reporting of certain measures of sexual risk, such as frequency of anal sex, number of partners and drug use, was not consistent across the studies, making it difficult to draw inferences from these data on the effects of PrEP on risk behaviour. Although all the studies included risk reduction counselling, only one study actually used a recognised risk reduction model (Molina et al., 2015) .
In addition, the studies reviewed here were all potentially biased.
For example, recall bias for sexual risk, which is influenced by the impact or meaning of an encounter (Grimm, 2010) , was not addressed in any of the studies. It is possible that not all sexual encounters were included in participants' reporting, and yet validity scales to adjust for recall bias during the statistical analyses were not included (Weinhardt et al., 1998) . Recruitment bias is another potential problem (Collumbein, Busza, Cleland, & Campbell, 2012) .
The participants recruited into the studies were all interested in PrEP as a form of protection against HIV, implying a self-awareness of risk behaviour that may not be found in the general MSM population.
Notwithstanding the methodological shortcomings described above, it is always more difficult to draw inferences from a collection of studies such as those reviewed here that have different designs
and that have different variables collected from different populations, in different places.
| CONCLUSION
We are presently in an optimistic period of biomedical advances to prevent HIV (Punyacharoensin et al., 2016) . However, in view of the gaps in the literature described herein, researchers must continue to investigate new ways to frame the discussion and messaging around STI prevention in a way that is meaningful to the individual, in order to reduce the social, physiological, psychological and financial burden of STIs.
| RELEVANCE TO CLINICAL PRACTICE
In an era where HIV prevention methods are rapidly improving, changing the perceived threat of disability or death, strategies for STI prevention and reducing sexual risk behaviour cannot remain stagnant. Nurses, community health workers, doctors, outreach workers, social workers are all well positioned to promote sexual health through the dissemination of accurate information to the communities they serve, including marginalised MSM throughout the world.
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